Key Takeaways Eli Lilly's TRIUMPH-4 trial showed retatrutide met all primary and key secondary endpoints.The drug delivered substantial weight loss and knee pain reduction across both tested doses.Higher adverse events led to increased discontinuations as Eli Lilly advances seven more studies.Shares of Eli Lilly (LLY) rose nearly 2% on Thursday after the company announced that a late-stage study evaluating its experimental once-weekly weight-loss drug, retatrutide, met all primary and key secondary endpoint ...